AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
ABBV News
Abbvie ((ABBV)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...
Abbvie ((ABBV)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...
Abbvie ((ABBV)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...
Analyst ratings
61%
of 31 ratingsMore ABBV News
Abbvie ((ABBV)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...
Abbvie ((ABBV)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...
Abbvie ((ABBV)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock po...
AbbVie (ABBV) has agreed to acquire the lead drug program from Gilgamesh Pharmaceuticals for up to $1.2 billion. The deal centers on bretisilocin, an experiment...
AbbVie Inc. ABBV announced Monday that it will acquire Gilgamesh Pharmaceuticals Inc.’s lead investigational candidate for moderate-to-severe major depressive d...
Raymond James analyst Gary Nachman notes AbbVie (ABBV) announced the proposed acquisition of Bretisilocin from Gilgamesh Pharmaceuticals for a deal value of up...
AbbVie (NYSE:ABBV) has agreed to acquire from Gilgamesh Pharmaceuticals its lead investigational candidate, Bretisilocin, for up to $1.2 billion. The deal incl...
